BridgeBio Pharma Q1 2024 Earnings Report

BridgeBio Pharma EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.40
• Beat/Miss: Beat by +$0.35
• One Year Ago EPS: N/A

BridgeBio Pharma Revenue Results

• Actual Revenue: $211.12 million
• Expected Revenue: $140.06 million
• Beat/Miss: Beat by +$71.06 million
• YoY Revenue Growth: N/A

BridgeBio Pharma Announcement Details

• Quarter: Q1 2024
• Date: 5/2/2024
• Time: N/A
• Conference Call Date: Thursday, May 2, 2024
• Conference Call Time: 7:00AM ET

BridgeBio Pharma (NASDAQ:BBIO), a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.